Day: March 11, 2025

Total revenues of $1.0 billion, up 13.9% and System-wide sales of $1.2 billion, up 7.4% Income from operations margin of 3.9% and Restaurant level operating profit margin of 20.1% Net income of $18.9 million and Adjusted EBITDA of $113.8 million 50 system-wide restaurants opened across 19 statesBRADENTON, Fla., March 11, 2025 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 29, 2024 (“Q4 2024”) and the 52-week fiscal year ended December 29, 2024 (“2024”) compared to the fourteen weeks ended December 31, 2023 (“Q4 2023”) and the 53-week fiscal year ended December 31, 2023 (“2023”) and provided an outlook for the 52-week fiscal year...

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – – Plan to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for both monotherapy and combination therapy for WTX-124 in select indications – – Interim data from Phase 1/1b clinical trial of WTX-124 as monotherapy and in combination with pembrolizumab anticipated to be released in the fourth quarter of 2025 – – On track to initiate Phase 1/2 dose– and regimen-finding clinical trial of WTX-330 by the end of the first quarter of 2025 – WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq:...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectively Over 5,000 patients treated to date Initiated commercial production of CARVYKTI® at a Novartis production facility Spain’s national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patients Cash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial runway into the second quarter of fiscal year 2026SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2024, and key corporate highlights. “We are...

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219’s transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025 Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026BOSTON and SAN DIEGO,...

SHANGHAI, March 11, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter and full year ended December 31, 2024. Ziyu Shen, ECARX Chairman and CEO, commented, “2024 was a remarkable year for ECARX, marked by significant milestones and progress across our business. We continued to execute on our strategic vision, further strengthening the unique value proposition we offer global automakers who are seeking cutting-edge, cost-effective solutions to distinguish themselves from the competition. We are capitalizing on this growing demand with our innovative product portfolio, diverse customer base, and strategic global partnerships. This is clearly reflected in our strong performance for full year 2024, with revenue...

Delivers Fourth Quarter Revenue Growth of 41.8% Driven by Broad-Based Strength Across All Segments Narrows Adjusted Net Loss for the Quarter, Continuing Path to Improved Profitability Delivers on Goal to Produce First Ever Quarter of Positive Adjusted EBITDA in the Fourth Quarter Full-year Sales Surpassed $100 Million, Backed by over 80% of Sales from Recurring Customers Introduces 10-year Committed and Contracted Backlog, Reflecting Accelerating Long-Term Demand Across Segments Initiates 2025 Guidance of Healthy Double-digit Revenue Growth and First Ever Full Year of Positive Adjusted EBITDA TEL AVIV, Israel and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader of vision and light control technologies, today announced financial results for the fourth quarter and full...

BEIJING, March 11, 2025 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced its unaudited financial results for the quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 HighlightsTotal paid enterprise customers1 in the twelve months ended December 31, 2024 were 6.1 million, an increase of 17.3% from 5.2 million in the twelve months ended December 31, 2023. Average monthly active users (MAU)2 for the fourth quarter of 2024 were 52.7 million, an increase of 27.9% from 41.2 million for the same quarter of 2023. Average MAU for the full year of 2024 were 53.0 million, an increase of 25.3% from 42.3 million for the full year of 2023.Revenues for the fourth quarter of 2024 were RMB1,823.6 million...

VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three months and the year ended December 31, 2024. All dollar amounts are in US dollars (US$). “The Company achieved strong financial results in 2024, maintaining a solid balance sheet,” said CEO Dan Dickson. “Higher realized prices fueled robust revenue, with mine operating cash flow reaching $72.3 million. With the Terronera project nearing completion and Pitarrilla progressing toward an economic assessment, we are well-positioned for sustained growth and value creation”. 2024 HighlightsProduction at the Higher end of the Updated 2024 Guidance: Production hit the higher end of the revised guidance of 7.3 to 7.6 million AgEq...